CLINUVEL PHARMACEUTICALS LTD (Seite 1693)
eröffnet am 24.04.07 13:00:35 von
neuester Beitrag 17.05.24 07:54:43 von
neuester Beitrag 17.05.24 07:54:43 von
Beiträge: 22.264
ID: 1.126.403
ID: 1.126.403
Aufrufe heute: 19
Gesamt: 4.027.006
Gesamt: 4.027.006
Aktive User: 0
ISIN: AU000000CUV3 · WKN: A0JEGY
9,3225
EUR
-0,53 %
-0,0500 EUR
Letzter Kurs 21.05.24 Lang & Schwarz
Neuigkeiten
28.03.24 · globenewswire  |
07.03.24 · EQS Group AG |
05.03.24 · globenewswire |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,1800 | +28,02 | |
| 1,9900 | +27,56 | |
| 1,2900 | +24,04 | |
| 2,7200 | +21,97 | |
| 1,0200 | +20,60 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 2,0600 | -14,88 | |
| 2,9000 | -16,91 | |
| 2,2001 | -20,57 | |
| 0,8401 | -23,63 | |
| 0,7601 | -23,98 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 57.985.059 von gainforall am 14.06.18 13:07:44
Ich würde eher sagen das es so mit 49-51% Chance eintreten wird. Aber sehr gute Einschätzung.
Zitat von gainforall: Sehr gute Einschätzung, sollte mit 70 bis 80%iger Wahrscheinlichkeit so eintreffen, wenn nicht vorher kurstreibende positive Nachrichten veröffentlicht werden!
Ich würde eher sagen das es so mit 49-51% Chance eintreten wird. Aber sehr gute Einschätzung.
Sehr gute Einschätzung, sollte mit 70 bis 80%iger Wahrscheinlichkeit so eintreffen, wenn nicht vorher kurstreibende positive Nachrichten veröffentlicht werden!
Antwort auf Beitrag Nr.: 57.984.453 von Cwebb am 14.06.18 12:00:11Ich gehe davon aus, dass es nochmals runter geht. Deshalb habe ich gestern erst 50% meiner noch fehlenden Stücke gekauft. Ich denke 6.80 sehen wir nochmals in den nächsten 10 Tagen. Aber nur meine Meinung.
da gehts aber schon wieder sehr schnell aufwärts nach dieser Korrektur. Geht es womöglich nochmals runter oder wars das schon...
Antwort auf Beitrag Nr.: 57.979.296 von printguru am 13.06.18 19:55:49Bin in Wirecard (noch) drin, hat aber nix mit CUV zu tun..
und danke Gregory für den Chart :-)
und danke Gregory für den Chart :-)
Trading Spotlight
Dankeschön
Antwort auf Beitrag Nr.: 57.981.642 von ODI01 am 14.06.18 06:37:44
The University of Arizona is moving to commercialize two faculty-invented drug compounds that could help protect people from sun damage and skin cancer by boosting the skin’s natural pigment.
The chemical compounds, developed by professors Minying Cai and Victor Hruby in the UA department of chemistry and biochemistry, were recently licensed to startup MCR Therapeutics, formed by Cai and Hruby last year.
Hruby is a regents professor emeritus who has been involved in several drug startups, and Cai is a longtime drug researcher who joined the UA in 1999 as a research scientist and has been a research professor since 2007.
Each hold appointments in the College of Science and the College of Medicine and are members of the Arizona Cancer Center and the UA Bio5 Institute.
The peptides developed by Cai and Hruby target certain melanocortin receptors, which stimulate the natural production of skin cells that produce melanin — the pigment responsible for skin color that provides protection against harmful ultraviolet light.
With 3 million new cases diagnosed each year, skin cancer is one of the most common and deadly cancers. More than 9,300 people are expected to die from the disease in 2018 in the U.S. alone.
The new drugs could help protect people from skin cancer as a more effective alternative to traditional sunscreens.
Sunscreen lotions can prevent skin damage from ultraviolet radiation, but they are often applied incorrectly, can easily wash away and are only partially effective compared to natural tanning or pigmentation, Hruby said.
Drugs based on the new peptides could be administered via a nasal spray, intraperitoneal injection into the body cavity or perhaps a skin patch, Hurby said.
Though the peptides have shown promise in preclinical studies, they would still need to go through a series of human clinical trials to win regulatory approval.
Hruby said he and Cai are talking with two companies about partnering or collaborating with them to push the research forward.
“We think were within one or two years of clinical trials, all we have to do is get a partner to do the necessary things with the FDA,” he said.
Melanocortin receptors are known to play a role in other physiological aspects such as obesity, stress, cognition and mood, but MCR plans to initially focus on skin.
Cai and Hruby have worked together for years on drugs that target melanocortin receptors. In 2016, the pair licensed a startup company to develop a drug that showed promise in treating acute depression and related ailments by blocking the receptors.
And this isn’t the first time Hruby has shepherded a melanin-boosting drug to market.
In the 1980s, Hruby and another UA professor, the late Mac Hadley, invented a skin-darkening compound, afamelanotide, later known as Melanotan I, that was licensed to an Australian company.
The company, now known as Clinuvel, won European approval of the drug labeled as Scenesse to treat patients with erythropoietic protoporphyria, a rare disease that causes severe inflammation of the skin with exposure to sunlight.
A related drug known as Melanotan II is widely and illegally sold on the internet as an injectable tanning agent sometimes called the “Barbie drug.” It is banned in the U.S., Canada and Europe because it has not undergone proper testing and is known to cause serious side effects.
Hruby said the new peptides he and Cai have developed differ from the earlier compounds because they are selective in their action and hence don’t cause problematic side effects.
The research team worked with Tech Launch Arizona, the office of the UA that commercializes inventions stemming from UA research, to patent the technologies and advanced their business plan through the National Science Foundation I-Corps program.
They also received TLA asset-development funding to help ready their product for market.
bitte schön
Tucson Tech: UA licenses drugs to help prevent skin cancerThe University of Arizona is moving to commercialize two faculty-invented drug compounds that could help protect people from sun damage and skin cancer by boosting the skin’s natural pigment.
The chemical compounds, developed by professors Minying Cai and Victor Hruby in the UA department of chemistry and biochemistry, were recently licensed to startup MCR Therapeutics, formed by Cai and Hruby last year.
Hruby is a regents professor emeritus who has been involved in several drug startups, and Cai is a longtime drug researcher who joined the UA in 1999 as a research scientist and has been a research professor since 2007.
Each hold appointments in the College of Science and the College of Medicine and are members of the Arizona Cancer Center and the UA Bio5 Institute.
The peptides developed by Cai and Hruby target certain melanocortin receptors, which stimulate the natural production of skin cells that produce melanin — the pigment responsible for skin color that provides protection against harmful ultraviolet light.
With 3 million new cases diagnosed each year, skin cancer is one of the most common and deadly cancers. More than 9,300 people are expected to die from the disease in 2018 in the U.S. alone.
The new drugs could help protect people from skin cancer as a more effective alternative to traditional sunscreens.
Sunscreen lotions can prevent skin damage from ultraviolet radiation, but they are often applied incorrectly, can easily wash away and are only partially effective compared to natural tanning or pigmentation, Hruby said.
Drugs based on the new peptides could be administered via a nasal spray, intraperitoneal injection into the body cavity or perhaps a skin patch, Hurby said.
Though the peptides have shown promise in preclinical studies, they would still need to go through a series of human clinical trials to win regulatory approval.
Hruby said he and Cai are talking with two companies about partnering or collaborating with them to push the research forward.
“We think were within one or two years of clinical trials, all we have to do is get a partner to do the necessary things with the FDA,” he said.
Melanocortin receptors are known to play a role in other physiological aspects such as obesity, stress, cognition and mood, but MCR plans to initially focus on skin.
Cai and Hruby have worked together for years on drugs that target melanocortin receptors. In 2016, the pair licensed a startup company to develop a drug that showed promise in treating acute depression and related ailments by blocking the receptors.
And this isn’t the first time Hruby has shepherded a melanin-boosting drug to market.
In the 1980s, Hruby and another UA professor, the late Mac Hadley, invented a skin-darkening compound, afamelanotide, later known as Melanotan I, that was licensed to an Australian company.
The company, now known as Clinuvel, won European approval of the drug labeled as Scenesse to treat patients with erythropoietic protoporphyria, a rare disease that causes severe inflammation of the skin with exposure to sunlight.
A related drug known as Melanotan II is widely and illegally sold on the internet as an injectable tanning agent sometimes called the “Barbie drug.” It is banned in the U.S., Canada and Europe because it has not undergone proper testing and is known to cause serious side effects.
Hruby said the new peptides he and Cai have developed differ from the earlier compounds because they are selective in their action and hence don’t cause problematic side effects.
The research team worked with Tech Launch Arizona, the office of the UA that commercializes inventions stemming from UA research, to patent the technologies and advanced their business plan through the National Science Foundation I-Corps program.
They also received TLA asset-development funding to help ready their product for market.
https://tucson.com/business/tucson-tech-ua-licenses-drugs-to…
Könnte jemand diesen Artikel kopieren und reinstell,Seite ist für den europäischen Raum gesperrt
Könnte jemand diesen Artikel kopieren und reinstell,Seite ist für den europäischen Raum gesperrt
Glückwunsch an alle, die heute die chance genutzt haben. Denke in der laufenden korrektur wird es keine markant tieferen kurse mehr geben.
Sollte sich fundamental nicht was zum negativen ändern, werden wir spätestens in zwei oder drei monaten wieder deutlich höher stehen.
Sollte sich fundamental nicht was zum negativen ändern, werden wir spätestens in zwei oder drei monaten wieder deutlich höher stehen.
Was ein Kasperletheater heute.
Hat hier keiner außer Schnitzel Eier ?
Schon krass, der Kurs kann auch mal fallen, wär hätte es gedacht.
Troll Printis großer Tag und der Rest hüpft nervös herum und belästigt Dr.Homm: hilfe Herr Homm der Kurs ist 10 % gefallen ich kack mir in die Buxe.
Hat hier keiner außer Schnitzel Eier ?
Schon krass, der Kurs kann auch mal fallen, wär hätte es gedacht.
Troll Printis großer Tag und der Rest hüpft nervös herum und belästigt Dr.Homm: hilfe Herr Homm der Kurs ist 10 % gefallen ich kack mir in die Buxe.
Durchsuchen
07.03.24 · EQS Group AG · Clinuvel Pharmaceuticals |
06.01.24 · wallstreetONLINE NewsUpdate · Evotec |
06.01.24 · wallstreetONLINE Redaktion · Evotec |
04.10.23 · wO Chartvergleich · Bayer |
20.09.23 · wO Chartvergleich · Borussia Dortmund |